심장 모니터링 및 심장 리듬 관리 시장 : 디바이스 유형별, 치료 유형별, 기술별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Cardiac Monitoring & Cardiac Rhythm Management Market is projected to grow by USD 30.84 billion at a CAGR of 5.13% by 2032.

Executive Introduction to Cardiac Monitoring and Rhythm Management

Cardiac monitoring and cardiac rhythm management are moving from episodic diagnosis to continuous, data-driven cardiovascular care. The industry spans resting and ambulatory ECG, Holter and event monitoring, mobile cardiac telemetry, implantable loop recorders, pacemakers, implantable cardioverter-defibrillators, cardiac resynchronization therapy devices, remote monitoring platforms, and connected wearable sensors.

Demand is anchored in verified public-health need: the World Health Organization identifies cardiovascular disease as the leading cause of death globally, responsible for an estimated 17.9 million deaths annually. Aging populations, atrial fibrillation detection, heart failure management, post-acute monitoring, and remote patient monitoring reimbursement are expanding adoption across hospitals, ambulatory settings, and home care.

Transformative Shifts in the Cardiac Care Landscape

The landscape is being reshaped by a shift from device-centric care to connected cardiac ecosystems. Hospitals and electrophysiology practices are integrating implantable cardiac devices, patches, cloud ECG review, and patient apps to reduce time to diagnosis and identify arrhythmias earlier. Remote monitoring is increasingly positioned as a standard pathway for pacemaker, ICD, and CRT follow-up, supported by clinical guidelines and payer recognition in several mature markets.

Regulatory and supply-chain changes are also influencing strategy. The European Union Medical Device Regulation has raised clinical evidence and post-market surveillance expectations, while the U.S. FDA continues to expand digital health oversight for software as a medical device. Manufacturers are responding with cybersecurity-by-design, interoperability, battery longevity, miniaturization, and workflow automation.

Cumulative Impact of Artificial Intelligence on Cardiac Monitoring

Artificial intelligence is adding cumulative value across detection, triage, workflow, and longitudinal risk management. FDA-cleared AI-enabled ECG and cardiac monitoring tools already support arrhythmia classification, atrial fibrillation detection, QT assessment, and prioritization of abnormal recordings. The near-term impact is strongest where AI reduces clinician review burden and accelerates escalation of high-risk events.

However, AI adoption depends on transparent validation, representative datasets, explainability, and integration with electronic health records. Leaders are prioritizing clinically validated algorithms, bias monitoring, cybersecurity, and human-in-the-loop review because cardiac rhythm decisions can trigger anticoagulation, ablation referral, device implantation, or emergency intervention.

Key Regional Insights Across Global Cardiac Monitoring Markets

North America leads adoption through established electrophysiology infrastructure, high use of implantable rhythm devices, FDA-cleared digital health tools, and reimbursement pathways for remote physiologic monitoring. Europe remains a major innovation and clinical-evidence hub, with adoption shaped by national health technology assessment, GDPR requirements, and the EU Medical Device Regulation. Asia-Pacific is expanding rapidly as China, Japan, India, South Korea, and Australia invest in hospital capacity, digital health, chronic disease management, and aging-care infrastructure.

Latin America shows rising demand in Brazil and Mexico, supported by expanding private cardiology services and increasing awareness of atrial fibrillation and heart failure monitoring, but adoption is constrained by uneven reimbursement and specialist access. The Middle East, particularly Gulf health systems, is investing in tertiary cardiac centers, digital hospitals, and connected care models aligned with national health transformation programs. Africa's opportunity is tied to scalable ECG access, mobile health, workforce training, and capacity building to improve early cardiovascular diagnosis across underserved settings.

Key Group Insights for Cardiac Monitoring and CRM Adoption

ASEAN demand is supported by urban hospital expansion, digital health adoption, and rising cardiovascular risk factors, although procurement and reimbursement maturity vary widely by country. The GCC is advancing premium cardiac care through public investment, private hospital growth, and medical tourism, with remote monitoring aligned to national digital health strategies. The European Union emphasizes regulated innovation, clinical evidence, privacy, cybersecurity, and interoperability, making compliance with MDR and GDPR a competitive differentiator for cardiac monitoring and cardiac rhythm management technologies.

BRICS markets combine large cardiovascular patient pools with improving local manufacturing, digital infrastructure, and price-sensitive procurement, creating demand for scalable ECG, ambulatory monitoring, and value-tier implantable devices. G7 countries remain the core demand base for advanced CRM devices, remote cardiac monitoring, and AI-enabled ECG analytics due to mature reimbursement systems, specialist networks, and aging populations. NATO members increasingly emphasize cyber-resilient medical infrastructure and secure connected devices as remote monitoring expands across hospital, ambulatory, and home-care environments.

Key Country Insights in Cardiac Monitoring and CRM

The United States remains the largest commercial opportunity, supported by advanced electrophysiology networks, FDA pathways, and reimbursement for remote physiologic and therapeutic monitoring. Canada prioritizes public-system procurement, clinical evidence, and equitable access across urban and remote populations, while Mexico and Brazil are expanding private-sector cardiology, ambulatory ECG services, and hospital-based rhythm management. The United Kingdom, Germany, France, Italy, and Spain combine strong clinical capacity with cost-effectiveness scrutiny, national procurement controls, and growing demand for remote follow-up; Russia's market is shaped by localization policies, procurement controls, and public-sector purchasing dynamics.

China is scaling domestic cardiac device production, hospital modernization, and digital health infrastructure, while India offers high-volume adoption potential through affordability, telecardiology, and expanding tertiary cardiac care. Japan leads in aging-related rhythm management demand, supported by high clinical acceptance of pacemakers, ICDs, and remote follow-up for older patients. Australia supports remote cardiac care for geographically dispersed patients and established digital health programs, while South Korea combines digital health sophistication, connected hospitals, and strong technology adoption for advanced cardiac monitoring workflows.

Actionable Recommendations for Cardiac Device Industry Leaders

Industry leaders should align portfolios with continuous care models by integrating implantable devices, ambulatory monitors, AI analytics, remote monitoring dashboards, and EHR connectivity. Product strategy should emphasize diagnostic accuracy, clinician workflow efficiency, cybersecurity, battery performance, patient adherence, and evidence generation in real-world settings.

Commercial teams should tailor market access by region: demonstrate cost offsets in mature markets, support capacity building in emerging markets, and develop value tiers for public and private buyers. Partnerships with hospitals, payers, telehealth platforms, and cloud providers can accelerate adoption, but governance for data privacy, algorithm validation, and post-market surveillance must remain central.

Research Methodology for Evidence-Based Market Intelligence

This executive summary is built on secondary research, regulatory intelligence, clinical guideline review, public-health datasets, technology trend analysis, and peer-reviewed evidence. Core reference points include WHO cardiovascular disease statistics, U.S. FDA digital health and medical device clearances, European regulatory frameworks, payer policy updates, and clinical literature on remote cardiac monitoring, implantable cardiac devices, ECG analytics, and arrhythmia detection.

The methodology emphasizes triangulation across epidemiology, clinical practice, reimbursement, regulatory requirements, technology adoption, and regional health-system readiness. Insights are interpreted for strategic use in cardiac monitoring and cardiac rhythm management without relying on speculative claims, unverified market sizing, market share, or unsupported forecasts.

Conclusion: Connected Cardiac Care Defines the Next Growth Phase

Cardiac monitoring and cardiac rhythm management are becoming central to preventive, personalized, and connected cardiovascular care. Adoption is supported by the global burden of cardiovascular disease, aging demographics, increased arrhythmia screening, remote patient monitoring, and the maturation of AI-enabled ECG analytics.

Competitive advantage will belong to organizations that combine clinical-grade devices with interoperable software, validated algorithms, secure data infrastructure, and strong market access evidence. As care shifts from hospitals to hybrid and home-based models, trusted connected cardiac ecosystems will define the next phase of industry leadership.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cardiac Monitoring & Cardiac Rhythm Management Market, by Device Type

• 7.1. External Monitoring Devices
• 7.2. Implantable Monitoring Devices

8. Cardiac Monitoring & Cardiac Rhythm Management Market, by Therapy Type

• 8.1. Cardiac Resynchronization Therapy Devices
• 8.2. Implantable Cardioverter Defibrillators
  • 8.2.1. Subcutaneous
  • 8.2.2. Transvenous
• 8.3. Pacemakers
  • 8.3.1. Biventricular
  • 8.3.2. Dual Chamber
  • 8.3.3. Single Chamber

9. Cardiac Monitoring & Cardiac Rhythm Management Market, by Technology

• 9.1. Mobile
  • 9.1.1. Smartphone Based
  • 9.1.2. Tablet Based
• 9.2. Remote Patient Monitoring
• 9.3. Telehealth
• 9.4. Wireless
  • 9.4.1. Bluetooth
  • 9.4.2. Zigbee

10. Cardiac Monitoring & Cardiac Rhythm Management Market, by Application

• 10.1. Arrhythmia Detection
  • 10.1.1. Atrial Fibrillation
  • 10.1.2. Ventricular Arrhythmia
• 10.2. Heart Failure Monitoring
  • 10.2.1. Fluid Status Monitoring
  • 10.2.2. Weight Monitoring
• 10.3. Postoperative Monitoring

11. Cardiac Monitoring & Cardiac Rhythm Management Market, by End User

• 11.1. Ambulatory Care Centers
• 11.2. Home Healthcare
• 11.3. Hospitals

12. Cardiac Monitoring & Cardiac Rhythm Management Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Cardiac Monitoring & Cardiac Rhythm Management Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Cardiac Monitoring & Cardiac Rhythm Management Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. ACS Diagnostics
• 16.3. Alivecor, Inc.
• 16.4. Asahi Kasei Corporation
• 16.5. Baxter International Inc.
• 16.6. Biotronik SE & Co KG
• 16.7. Boston Scientific Corporation
• 16.8. BPL Medical Technologies Private Limited
• 16.9. GE Healthcare
• 16.10. HeartFlow Holding, Inc.
• 16.11. Koninklijke Philips N.V.,
• 16.12. Lepu Medical Technology(Beijing)Co.,Ltd.
• 16.13. Medtronic PLC
• 16.14. Microport Scientific Corporation
• 16.15. Nihon Kohden Corporation
• 16.16. Qardio, Inc.
• 16.17. Schiller AG
• 16.18. Spandan
• 16.19. Tricog Health
• 16.20. Zoll Medical Corporation